NASDAQ:RGNX
REGENXBIO Inc. Stock News
$15.74
+0.300 (+1.94%)
At Close: May 13, 2024
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
06:12pm, Monday, 01'st Mar 2021
Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Week 7 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An Edge
07:26am, Sunday, 14'th Feb 2021
Week 7 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An Edge
ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
07:05am, Friday, 05'th Feb 2021
ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conferenc
REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021
07:05am, Monday, 01'st Feb 2021
ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking
REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:05am, Monday, 11'th Jan 2021
ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40
REGENXBIO Announces Pricing Of Public Offering Of Common Stock
07:05am, Friday, 08'th Jan 2021
ROCKVILLE, Md., Jan. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 4,260,000 shares of its common stock at the price of $47.00
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program
12:02pm, Wednesday, 06'th Jan 2021
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million
04:19pm, Tuesday, 22'nd Dec 2020
ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy base
Regenxbio: Championing Gene Therapy
08:55am, Saturday, 19'th Dec 2020
Back in 2019, the Zolgensma approval validated Regenxbio's NAV technology platform for gene delivery. Despite a slow start, Zolgensma recently hit $1B in cumulative sales. Regenxbio's organic pipeline
4 Biotechs That Could Be Potential Acquisition Targets in 2021
10:32am, Thursday, 17'th Dec 2020
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
ROCKVILLE, Md., Dec. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy base
REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I
07:05am, Tuesday, 01'st Dec 2020
ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based
REGENXBIO to Present at Upcoming Investor Conferences
04:05pm, Monday, 23'rd Nov 2020
ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy base
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript
12:01am, Thursday, 05'th Nov 2020
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript